(NASDAQ: CBUS) Cibus's forecast annual revenue growth rate of 133.06% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.72%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.78%.
Cibus's revenue in 2025 is $3,794,000.On average, 7 Wall Street analysts forecast CBUS's revenue for 2026 to be $485,182,446, with the lowest CBUS revenue forecast at $334,166,831, and the highest CBUS revenue forecast at $569,972,666. On average, 6 Wall Street analysts forecast CBUS's revenue for 2027 to be $3,042,785,504, with the lowest CBUS revenue forecast at $715,071,421, and the highest CBUS revenue forecast at $7,466,641,918.
In 2028, CBUS is forecast to generate $7,710,373,086 in revenue, with the lowest revenue forecast at $3,894,487,516 and the highest revenue forecast at $11,701,810,238.